Clinical trial
Beta-Lactam Containing Regimen for the Shortening of Buruli Ulcer Disease Therapy: Comparison of 8 Weeks Standard Therapy (Rifampicin Plus Clarithromycin) vs. 4 Weeks Standard Plus Amoxicillin/Clavulanate Therapy [RC8 vs. RCA4]
NCT05169554 is registered in ClinicalTrials.gov with Fundacion Agencia Aragonesa para la Investigacion y Desarrollo (ARAID) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Beta-Lactam Containing Regimen for the Shortening of Buruli Ulcer Disease Therapy: Comparison of 8 Weeks Standard Therapy (Rifampicin Plus Clarithromycin) vs. 4 Weeks Standard Plus Amoxicillin/Clavulanate Therapy [RC8 vs. RCA4]
- Lead sponsor
- Fundacion Agencia Aragonesa para la Investigacion y Desarrollo (ARAID)
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- December 1, 2021
- Completion date
- May 31, 2026
- Enrollment
- 140 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.